# Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency

> **NCT01563926** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 168 (actual)

## Conditions studied

- Growth Hormone Disorder
- Growth Hormone Deficiency in Children
- Genetic Disorder
- Turner Syndrome

## Interventions

- **DRUG:** somatropin

## Key facts

- **NCT ID:** NCT01563926
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-10-23
- **Primary completion:** 2002-10-10
- **Final completion:** 2002-10-10
- **Target enrollment:** 168 (ACTUAL)
- **Last updated:** 2017-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01563926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01563926, "Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01563926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*